Top executives at generic drug giant Mylan “could not be clearer” that they are not working solely or primarily for shareholders when spurning Teva Pharmaceutical Industries’ takeover proposal and pushing to buy Perrigo instead, according to an analyst who met with Mylan management last week.
“Management argued it has to consider employees, suppliers etc., not just answer to shareholders” when considering Teva’s $82-per-share, more than $40 billion offer, Sanford Bernstein analyst Ronny Gal wrote in a research note to clients.
“When we pushed back, asking if the position here is that Mylan can ignore shareholder wishes,” executives reiterated that Teva was the “wrong company” to merge with, Mr. Gal wrote.
He said Mylan contends a hostile takeover by Israel’s Teva would take years because “management will oppose it all the way.”
Mylan executives have been meeting privately with investors to garner support for their company’s unsolicited bid for over-the-counter medications specialist Perrigo, which Perrigo’s board has rejected. Besides needing the nod from Ireland-based Perrigo, the acquisition would have to be approved by Mylan shareholders.
Mylan is run from its operations base in Cecil.
Read More
Mr. Gal said he wasn’t convinced of the Perrigo deal’s merits. “Our preliminary analysis suggests Mylan is giving most/all the value created in the deal to Perrigo shareholders,” he wrote. “We heard nothing from Mylan today that would change that view.”
Mylan chairman Robert Coury has denounced a combination with Teva as lacking “sound industrial logic or cultural fit.”
Still, Mr. Coury told some investors that he might consider merging with Teva down the road, as long as Mylan was the buyer, Reuters news service reported.
Mylan CEO Heather Bresch said the logic behind Mr. Coury’s comments was that Mylan has a better management team, integrated global supply chain, as well as superior track record with acquisitions, the news service said.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.